GANX

Conviction 2HealthcareScan · Mon, Aug 10, 2026

Bearish engulfing

GANX$1.77-2.75%

ResistanceSupportVol 14

Vol MA14 372.35K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Gain Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.gaintherapeutics.com ↗

Price1.77

Change-2.75%

Gap+1.10%

Rel volume0.11×

Avg volume502.44K

Avg $ vol872.52K

SMA 201.75

SMA 501.78

SMA 2002.19

Price vs 50-0.76%

Price vs 200-19.19%

MA stackbearish

50/200 cross—

Supertrenddown · 2.03

RSI (14)50

MACD hist0.01

MACD crossbull · 3d

Stoch %K / %D48 / 60

ADX (14)8

+DI / −DI17 / 17

RSI divergence—

MACD divergence—

ATR %+6.26%

ADR %6.32%

52w high4.18

52w low1.46

From 52w high-57.66%

Above 52w low+21.23%

New 52w highNo

SqueezeOn · 9d

Bollinger width14.89%

%B0.57

Donchian pos60.00%

Donchian high1.89

Donchian low1.59

AVWAP (52w high)2.28

vs AVWAP high-22.26%

AVWAP (52w low)2.31

vs AVWAP low-23.35%

OBV trendFlat

Chaikin MF (20)-0.05

Today vs 20d0.11×

Avg vol (14d)372.35K

Avg vol (20d)502.44K

Avg $ vol (20d)872.52K

Market cap75.5M

RS 3m (vs SPY)-8.37%

RS 6m (vs SPY)-1.77%

RS line new highNo

Trend template0/8

Technical rank30.8

1 week+1.14%

1 month-1.67%

3 months-2.75%

6 months+1.14%

1 year+18.79%

YTD-44.34%

P/E-3.74

P/B5.39

P/S—

P/FCF-4.07

EPS-0.6100

Div yield—

ROE-143.94%

ROA-107.59%

Debt/Eq0.03

Current4.69

EV/EBITDA-3.19

Gross margin—

Net margin—

Rev growth0.00%

EPS growth1.23%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value59.33M

Revenue55.18K

Net income-5.61M

Gross profit—

Free cash flow-18.56M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out42.65M

Employees21

ListedThu, Mar 18, 2021

Free float35.62M

Float %92.6%

Short interest3.59M

Days to cover4.0d

Short volume59.0%

Squeeze score53 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.13 vs −$0.13

Last surprise0.0% beat

Setup gradeD

Conviction2 / 100

Pattern quality—

Tech rank30.8 / 100

Group rank86 / 100 · Leading

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmBearish engulfing

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in GANX

All disclosures →

No recent disclosed trades by Congress in GANX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GANX · 6 buys

Insider	Side	Shares	Value	Traded	Filed
GOLDSTEIN DOV A MD Director · Stock Option (right to buy) · 2026-07-15	Grant	25K	—	2026-07-15	2026-07-17
HASLER HANS PETER Director · Stock Option (right to buy) · 2026-07-15	Grant	25K	—	2026-07-15	2026-07-17
Riley Jeffrey Scott Director · Stock Option (right to buy) · 2026-07-15	Grant	25K	—	2026-07-15	2026-07-17
Melincoff Gwen A Director · Stock Option (right to buy) · 2026-07-15	Grant	25K	—	2026-07-15	2026-07-17
Islam Khalid Director · Stock Option (right to buy) · 2026-07-15	Grant	25K	—	2026-07-15	2026-07-17
Nicaise Claude Director · Stock Option (right to buy) · 2026-07-15	Grant	25K	—	2026-07-15	2026-07-17

SEC filings

EDGAR filings in GANX · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.